Invention Grant
- Patent Title: Compounds for targeted immunotherapy
-
Application No.: US15849436Application Date: 2017-12-20
-
Publication No.: US10548988B2Publication Date: 2020-02-04
- Inventor: Lixin Li
- Applicant: BIRDIE BIOPHARMACEUTICALS, INC.
- Applicant Address: KY Grand Cayman
- Assignee: Birdie Biopharmaceuticals, Inc.
- Current Assignee: Birdie Biopharmaceuticals, Inc.
- Current Assignee Address: KY Grand Cayman
- Agency: K&L Gates LLP
- Agent Louis C. Cullman; David Diamond
- Priority: CN201210248481 20120718
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C12P21/08 ; C07K16/00 ; A61K39/39 ; A61K31/4745 ; A61K47/68 ; A61K45/06

Abstract:
Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Public/Granted literature
- US20180177887A1 COMPOUNDS FOR TARGETED IMMUNOTHERAPY Public/Granted day:2018-06-28
Information query